stoxline Quote Chart Rank Option Currency Glossary
InMed Pharmaceuticals Inc. (INM)
0.4141  -0.009 (-2.15%)    12-05 15:58
Open: 0.4292
High: 0.4299
Volume: 59,143
Pre. Close: 0.4232
Low: 0.4023
Market Cap: 1(M)
Technical analysis
2023-12-05 4:20:51 PM
Short term     
Mid term     
Targets 6-month :  0.62 1-year :  0.72
Resists First :  0.53 Second :  0.62
Pivot price 0.4
Supports First :  0.38 Second :  0.29
MAs MA(5) :  0.43 MA(20) :  0.4
MA(100) :  0.73 MA(250) :  1.14
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  61 D(3) :  64.5
RSI RSI(14): 44.4
52-week High :  3.02 Low :  0.29
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ INM ] has closed below upper band by 42.1%. Bollinger Bands are 56.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.43 - 0.43 0.43 - 0.44
Low: 0.4 - 0.4 0.4 - 0.4
Close: 0.41 - 0.42 0.42 - 0.42
Company Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Headline News

Thu, 30 Nov 2023
How Will the Market React to InMed Pharmaceuticals Inc (INM) Stock Getting a Bullish Rating - InvestorsObserver

Thu, 30 Nov 2023
Inmed's INM-089 improves retinal function in in vivo preclinical AMD disease model - BioWorld Online

Wed, 29 Nov 2023
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration - Yahoo Finance

Wed, 08 Nov 2023
InMed Pharmaceuticals files to sell 12.57M shares for holders (NASDAQ:INM) - Seeking Alpha

Thu, 26 Oct 2023
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option ... - Yahoo Finance

Thu, 26 Oct 2023
Is it Time to Dump InMed Pharmaceuticals Inc (INM) Stock After it Has Gained 16.67% in a Week? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 7 (M)
Shares Float 3 (M)
Held by Insiders 0.1 (%)
Held by Institutions 3 (%)
Shares Short 5 (K)
Shares Short P.Month 4 (K)
Stock Financials
EPS 0.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.88
Profit Margin -147.9 %
Operating Margin -291 %
Return on Assets (ttm) -36.9 %
Return on Equity (ttm) -67.8 %
Qtrly Rev. Growth 181.1 %
Gross Profit (p.s.) 0.21
Sales Per Share 0.71
EBITDA (p.s.) -1.11
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio 8.34
PEG Ratio 0
Price to Book value 0.14
Price to Sales 0.58
Price to Cash Flow -0.39
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android